Rodwin Rozalyn L, Siddiq Namrah Z, Ehrlich Barbara E, Lustberg Maryam B
Section of Pediatric Hematology/Oncology, Department of Pediatrics, Yale School of Medicine, New Haven, CT, United States.
Section of Medical Oncology, Department of Medicine, Yale School of Medicine, New Haven, CT, United States.
Front Pain Res (Lausanne). 2022 Mar 14;3:864910. doi: 10.3389/fpain.2022.864910. eCollection 2022.
Chemotherapy induced peripheral neuropathy (CIPN) is an often severe and debilitating complication of multiple chemotherapeutic agents that can affect patients of all ages, across cancer diagnoses. CIPN can persist post-therapy, and significantly impact the health and quality of life of cancer survivors. Identifying patients at risk for CIPN is challenging due to the lack of standardized objective measures to assess for CIPN. Furthermore, there are no approved preventative treatments for CIPN, and therapeutic options for CIPN remain limited once it develops. Biomarkers of CIPN have been studied but are not widely used in clinical practice. They can serve as an important clinical tool to identify individuals at risk for CIPN and to better understand the pathogenesis and avenues for treatment of CIPN. Here we review promising biomarkers of CIPN in humans and their clinical implications.
化疗引起的周围神经病变（CIPN）是多种化疗药物常见的严重且使人衰弱的并发症，可影响所有年龄段、患有各种癌症诊断的患者。CIPN可在治疗后持续存在，并显著影响癌症幸存者的健康和生活质量。由于缺乏评估CIPN的标准化客观指标，识别有CIPN风险的患者具有挑战性。此外，目前尚无批准的CIPN预防性治疗方法，一旦CIPN发生，其治疗选择仍然有限。虽然已经对CIPN的生物标志物进行了研究，但在临床实践中尚未广泛应用。它们可作为一种重要的临床工具，用于识别有CIPN风险的个体，并更好地理解CIPN的发病机制和治疗途径。在此，我们综述了人类中CIPN有前景的生物标志物及其临床意义。
